Overview of NDC 51862-0580
NDC 51862-0580 corresponds to Budesonide (Enteric Coated), a medication manufactured and distributed by Mayne Pharma Inc. This drug is used primarily for the treatment of inflammatory conditions of the gastrointestinal tract, such as Crohn's disease and ulcerative colitis.
Market Context
Pharmaceutical Industry Trends
The pharmaceutical industry is undergoing significant changes driven by technological advancements, regulatory shifts, and evolving patient needs. Key trends include the integration of AI in drug development, the rise of personalized medicine, and the increasing transparency in drug supply chains through blockchain technology[3].
Drug Price Inflation
Drug price inflation is a critical factor in market analysis. According to Vizient's summer 2024 Pharmacy Market Outlook, the overall drug price inflation rate for pharmaceuticals in 2025 is projected to be 3.81%. This increase is partly due to the expanding indications of previously approved medications and the introduction of high-cost cell and gene therapies[2].
Market Size and Growth
Global Prescription Drug Market
The global prescription drug market has seen significant growth over the past few years. Between 2017 and 2022, the U.S. prescription drug market experienced an 8% growth in volume, while the rest of the world and OECD countries (excluding the U.S.) saw 13% and 10% growth, respectively. However, the U.S. market stands out with much higher average prices per unit compared to other regions[4].
Average Price Trends
In the U.S., the average price per unit of prescription drugs increased by 14% between 2017 and 2022, whereas prices in the OECD (excluding the U.S.) and the rest of the world decreased by 9% and 7%, respectively. By 2022, prices in the U.S. were 5.5 times those in the OECD (excluding the U.S.) and 7.7 times those in the rest of the world[4].
Price Projections for Budesonide (Enteric Coated)
Current Pricing
As of the latest available data, the pricing for Budesonide (Enteric Coated) under NDC 51862-0580 is not explicitly stated. However, given the general trend of drug price inflation, it is reasonable to expect some level of price increase.
Projected Price Inflation
Given the projected overall drug price inflation rate of 3.81% for 2025, it is likely that the price of Budesonide (Enteric Coated) will also increase. Here are a few scenarios:
- Conservative Estimate: If the price of Budesonide (Enteric Coated) follows the average inflation rate, a 3.81% increase can be expected.
- Moderate Estimate: Considering the drug's specific market dynamics and the potential for higher demand due to its use in chronic conditions, a slightly higher inflation rate, say 4-5%, could be anticipated.
- High Estimate: In a scenario where the drug experiences increased demand or supply chain disruptions, the price could rise more significantly, potentially exceeding 5%.
Impact of Market Trends
The integration of AI and other technological advancements in the pharmaceutical industry could lead to more efficient production and distribution, potentially stabilizing or even reducing prices in the long term. However, the immediate impact of these trends on the pricing of Budesonide (Enteric Coated) is likely to be minimal in the short term.
Regulatory and Supply Chain Considerations
Regulatory Environment
Changes in regulatory policies can significantly impact drug pricing. For instance, stricter regulations on patient data and drug safety could increase costs for manufacturers, which might be passed on to consumers. Mayne Pharma Inc., the manufacturer of Budesonide (Enteric Coated), must comply with these regulations, which could influence pricing[3].
Supply Chain Transparency
The use of blockchain technology to enhance supply chain transparency could reduce costs associated with counterfeit drugs and improve efficiency. However, the immediate benefits of this technology on the pricing of specific drugs like Budesonide (Enteric Coated) are still evolving[3].
Conclusion
The market analysis for Budesonide (Enteric Coated) under NDC 51862-0580 indicates that prices are likely to increase in line with the overall drug price inflation rate. Here are the key takeaways:
- Price Inflation: A projected increase of 3.81% to 5% in 2025.
- Market Trends: Technological advancements and regulatory changes may influence pricing in the long term.
- Global Context: The U.S. market continues to have significantly higher average prices per unit compared to other regions.
- Regulatory and Supply Chain Factors: Compliance with new regulations and the adoption of technologies like blockchain could impact pricing.
Key Takeaways
- Price Projections: Expect a price increase of 3.81% to 5% for Budesonide (Enteric Coated) in 2025.
- Market Dynamics: The pharmaceutical industry is undergoing significant changes driven by technology and regulatory shifts.
- Global Pricing: The U.S. market has higher prices compared to other regions.
- Regulatory Compliance: Manufacturers must comply with new regulations, which could affect pricing.
- Supply Chain Efficiency: Blockchain technology may improve supply chain transparency and efficiency.
FAQs
Q1: What is the primary use of Budesonide (Enteric Coated)?
A1: Budesonide (Enteric Coated) is primarily used for the treatment of inflammatory conditions of the gastrointestinal tract, such as Crohn's disease and ulcerative colitis.
Q2: Who manufactures Budesonide (Enteric Coated) under NDC 51862-0580?
A2: Mayne Pharma Inc. manufactures and distributes Budesonide (Enteric Coated) under NDC 51862-0580.
Q3: What is the projected drug price inflation rate for 2025?
A3: The projected overall drug price inflation rate for 2025 is 3.81% according to Vizient's summer 2024 Pharmacy Market Outlook.
Q4: How do technological advancements impact drug pricing?
A4: Technological advancements, such as AI and blockchain, can improve efficiency and reduce costs in the long term, but their immediate impact on specific drug prices is minimal.
Q5: Why are drug prices in the U.S. higher compared to other regions?
A5: Drug prices in the U.S. are higher due to a combination of factors including higher average prices per unit and a drug mix that skews towards more expensive compounds[4].
Sources
- FDA Report: NDC 51862-564 Kit Low-Ogestrel Drug Codes.
- Vizient Inc.: Vizient projects drug price inflation at 3.81%.
- Laboratorios Rubio: The Future of Pharma: 2025's Key Trends To Know.
- ASPE: ISSUE BRIEF - International Market Size and Prices.
Last updated: 2025-01-02
